Risankizumab (Skyrizi, AbbVie) is indicated 'for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy'.
The dosage schedule is available in the summary of product characteristics for risankizumab.
The list price of risankizumab is £3,326.09 per:
600 mg vial of concentrate for solution for intravenous infusion (excluding VAT; BNF online accessed July 2024)
360 mg doses of solution for injection for subcutaneous administration (excluding VAT; BNF online accessed July 2024)
180 mg doses of solution for injection for subcutaneous administration (excluding VAT; company submission).
The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence.